CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Novonesis

Mads Torry Smith, Director, Digital Transformation, Applied R&D

Rethinking Digital R&D: Lessons from Novonesis on Data & Scaling Industrial Biosolutions

Mads Torry Smith

Mads Torry Smith

Digital R&D Visionary

Across the life sciences industry, digital tools, AI and automation have become central to R&D strategies. But turning these investments into scalable, enterprise-wide impact remains an ongoing challenge for many organizations. In my experience leading digital transformation within Applied R&D at Novonesis, the limiting factor is rarely the tools themselves—it’s the operating model beneath them.


At Novonesis, we develop biosolutions based on enzymes, microbes, cultures and proteins that improve food production, agriculture, household care and industrial processes. These biosolutions are developed using advanced biological processes such as precision fermentation to solve real-world problems in more sustainable ways. Supporting that work requires digital systems that do more than store data. They must shorten experiment cycles, reduce manual data handling, enable collaboration across teams and make it easier to adopt new AI capabilities.


The Limits of Tailor-Made Systems


Most teams feel their science and workflows are special, and they are. This is especially true in biosolutions R&D, where production scale-up and application testing happen under real industrial conditions. The temptation is to respond with fully tailor-made systems for each group. That works for a while, but the maintenance burden grows, integrations become brittle and scaling insights across functions gets harder, not easier.


The risk is not just inefficiency. Custom-built systems often become a bottleneck as organizations try to scale, and without a shift, AI investments remain stuck in pilot mode.


The alternative is to tailor the experience without tailoring the core. Use modular, plug-and-play tools that can be combined as needed. Done well, this creates a stable foundation with flexibility at the edges and allows teams to evolve without constant rebuilds.


For example, one team can design and execute experiments automatically, while another reuses that same data for downstream analysis without reformatting or manual transfer. Similarly, modular systems allow outdated components to be replaced in weeks rather than requiring full system rebuilds.


It is easy to chase the newest tools, but real progress comes from getting the fundamentals right.


At Novonesis, teams use different combinations of shared tools to design experiments, execute them and combine data across functions for analysis. The solution feels tailored to each team, but remains standardized underneath. This makes systems easier to maintain, easier to update and far more scalable across the organization.


Connected Data for Modern R&D


Composable systems depend on data that can move reliably between teams and tools. This requires keeping data with the teams who understand it, while making it accessible across the organization.


That means clear ownership, strong documentation, consistent identifiers and built-in quality checks so data can be shared without losing meaning.


For a global biosolutions company, this is critical. Discoveries in one area often inform another. Enzymes used in household care may have applications in food production. Fermentation insights in agriculture may accelerate progress in human health. When data is structured and accessible, those connections happen faster and more consistently.


In practice, this shifts teams from “sending files” to “serving data.” Instead of searching for exports, teams can access ready-to-use datasets on demand. The result is less manual handling, higher data quality and a foundation that is immediately usable for AI.


From Local Data to Organizational Insight


When data is treated as belonging to one team, its value stays local. When it is treated as a shared asset with clear ownership and structure, it becomes a multiplier.


This shift improves outcomes in tangible ways. Teams spend less time cleaning and moving data and more time running experiments. Insights can be reused across functions instead of recreated. Collaboration becomes easier because teams are working from consistent, trusted data.


Clear roles make this work. Data producers ensure quality and structure. Data consumers use it as intended and provide feedback to improve it.


A simple but effective habit is intentional data planning: defining what to capture, where it lives, how it connects and why it matters. This aligns cross-functional teams and ensures data is useful beyond its original purpose.


Leadership and Change Management Matter Most


This transition is less about technology and more about leadership. Leaders must set expectations that move teams away from one-off builds and toward scalable solutions. Success should be measured not by how much data is stored, but by how effectively it is reused across the organization.


Equally important is helping teams understand why structured data matters. When positioned as a scientific enabler rather than administrative overhead, adoption improves.


At Novonesis, we reinforce this through leadership forums that emphasize data quality, clear data flows, stewardship and a culture of curiosity and exploration.


Preparing Data Foundations for AI


As AI evolves, the organizations that benefit most will be those with clean, connected, well-governed data. Without that foundation, new tools add complexity instead of value.


With the right foundation, the opposite is true. New capabilities can be introduced quickly, outdated tools can be retired smoothly and teams can adopt innovation without disruption.


We think of this as building a plug-and-play AI layer on top of a connected data foundation. That only works if core data is structured, accessible, and ready to use.


It is easy to chase the newest tools, but real progress comes from getting the fundamentals right: intentional data capture, respect for workflows, shared ownership and strong change management.


Instead of betting on tools that might mature into enterprise solutions, we focus on building modular systems that allow new capabilities to be added when they are ready. The specific platforms will evolve, but the ability to work with structured, connected data will remain a lasting advantage.


For life sciences companies, this is not just an IT consideration. It is a competitive necessity.


The companies that win will not be the ones with the most tools, but the ones that can scale insight across their organization.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Life sciences organizations are discovering that digital transformation delivers lasting value only when data foundations, scalability and research execution evolve together. This perspective highlights why disciplined data architecture and operationally grounded digital strategies are becoming essential to accelerating innovation across industrial biosolutions and modern R&D environments.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/mads-torry-smith-nwid-3252.html